Skip to content

Addex Therapeutics Ltd.

ADXN

CIK 0001574232

← back to feed
Revenue (TTM)
—
FY Dec 2025
Net Income (TTM)
6.48M
+166.8% YoY FY Dec 2025
EPS Diluted (TTM)
−0.12
+150.0% YoY FY Dec 2025
Gross Margin
—
FY Dec 2025
Operating Margin
—
FY Dec 2025
Net Margin
—
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
2.3M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
147.83M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings